Mild Cognitive Impairment
Conditions
Keywords
Memory
Brief summary
The purpose of the Lifestyle Intervention Study is to investigate the influence of a micronutrient supplement in combination with a comprehensive lifestyle intervention program on retinal amyloid, among patients with Mild Cognitive Impairment (MCI). Patients will be placed on supplement or placebo throughout their 18-month study participation. Patients will also be given lifestyle training on nutrition, physical activity, cognitive and social activity, meditation and sleep, which have all been proven to positively affect cognition over time. Throughout their participation, patients' cognitive functioning will be monitored with comprehensive imaging, neuropsychological testing, blood testing and study compliance.
Interventions
DIETARY_SUPPLEMENTBBH-1001 Brain Health Supplement
Treatment with supplement consisting of turmeric, fish oil, vitamin D and green tea extract OR placebo.
OTHERLifestyle Intervention
All patients will be given lessons on 6 areas of lifestyle: nutrition, physical activity, meditation, sleep hygiene, cognitive activity, and social activity.
DIETARY_SUPPLEMENTBrain Health Placebo
Treatment with placebo consisting of soybean oil
Sponsors
Cedars-Sinai Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 55 years of age * Experiencing memory, or cognitive problems
Exclusion criteria
* Patients \< 55 years of age * Previously diagnosed dementia; suspected dementia after clinical assessment by study physician at screening visit * Mini Mental State Examination (MMSE) score less than 20 points * Disorders affecting safe engagement in the intervention (e.g., malignant disease, major depression, psychiatric disease, symptomatic cardiovascular disease, revascularization within 1 year previously) * Unable to safely change diet * Patients without the means to visit the clinic on the assigned dates * Patients that cannot comply with the data gathering needs of the study * Severe loss of vision, hearing, or communicative ability * Disorders preventing cooperation as judged by the study physician * Coincident participation in another intervention trial * Allergy to any ingredient in the supplement or placebo (i.e. soybean oil) * Patients with gallstones due to possible interactions with turmeric * Participants who are unable to provide clearance from their physician to participate in the physical activity training, as well as confirmed by Dr. Sherzai during the neurological exam.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in retinal amyloid burden, as measured by retinal amyloid scan. | baseline and 18 months | Patients will be given a retinal scan at baseline, 6 months, 12 months and end of study (18 months). The retinal scanner is an device that measures the buildup of amyloid proteins in the brain via imaging of the eye. The change in amyloid buildup between each time point will be measured to determine effect of the interventions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Neuropsychology | baseline and 18 months | 1\) Cognitive performance measured by Neuropsychological Test Battery, evaluating several cognitive domains, which are sensitive measures for mild cognitive changes |
| Diagnosis of Dementia | baseline and 7-10 years | 2\) Incidence dementia and Alzheimer's disease (according to standard criteria, NINCDS-ADRDA). An extended follow-up of at least 7-10 years is needed to investigate the effect of the intervention on this outcome. |
| Change in Neuroimaging | baseline and 18 months | 3\) Neuroimaging via data review (structural and functional brain MRI and FDG-PET). |
| Change in Lab Results | baseline and 18 months | 4\) Serum and plasma lab tests (inflammatory, metabolic, lipid and glucose metabolism, serum vitamin levels) |
| Change in Vascular Risk Factors | baseline and 18 months | 5\) Vascular risk factor markers (blood pressure, blood glucose and HgA1c, lipid panel) |
Countries
United States
Contacts
Primary ContactWendy Weissberg, BS
Backup ContactAyesha Sherzai, MD
Outcome results
None listed